This review evaluates the staging capabilities of 18FPSMA-1007 PET/CT for initial staging and detection of recurrent prostate cancer (PCa). 18FPSMA-1007 is a novel radiotracer with favourable imaging characteristics, suggesting potential utility within the PCa management landscape.

The Arksey and O’Malley framework guided this review. PubMed/MEDLINE, EMBASE, EBSCO, and CENTRAL databases were used and relevant titles screened for eligibility. Inclusion criteria recruited all studies involving PCa patients undergoing initial staging or - in biochemical recurrence (BCR) evaluation with 18FPSMA 1007 PET/CT, and must be published in English.

From 404 database results; 343 titles were excluded for irrelevance and duplication. Of 61 eligible studies, 24 were excluded for not meeting the inclusion criteria, leaving 35 papers for full-text review and inclusion. Evidence was categorised into two themes: (1) Initial staging and (2) detection of recurrent Prostate Cancer. Findings highlight 18FPSMA-1007 PET/CT’s superior diagnostic accuracy and sensitivity over conventional imaging and other radiotracers, particularly for the detection of pelvic and locoregional disease. Limitations include poor specificity for bone lesions, inconsistent urinary excretion patterns, and high inter-reader variability.

18F-PSMA-1007 PET/CT demonstrates superior diagnostic accuracy and sensitivity in both initial staging and detection of prostate cancer recurrence; however, it is limited by poor specificity for bone lesions and inconsistent urinary excretion patterns. Prospective multicentre trials are required to clearly delineate its role in the initial staging of prostate cancer and detection of recurrent disease.